82394-25-0

Basic information

• Product Name: 1-N-NONYLPIPERAZINE
• Synonyms: 1-NONYLPIPERAZINE;1-N-NONYLPIPERAZINE;1-(1-NONYL)-PIPERAZINE;Nonylpiperazine;1-N-NONYLPIPERAZINE 98%;1-(Non-1-yl)piperazine 98%;1-(Piperazin-1-yl)nonane;1-(Non-1-yl)piperazine98%
• CAS NO: 82394-25-0
• Molecular Formula: C₁₃H₂₈N₂
• Molecular Weight: 212.37
• Mol File: 82394-25-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 105 °C
• Flash Point: 87.6 °C
• Appearance: /
• Density: 0.86 g/cm³
• Vapor Pressure: 0.00261mmHg at 25°C
• Refractive Index: 1.456
• CAS DataBase Reference: 1-N-NONYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-NONYLPIPERAZINE(82394-25-0)
• EPA Substance Registry System: 1-N-NONYLPIPERAZINE(82394-25-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 82394-25-0(Hazardous Substances Data)

Usage

General Description

1-N-Nonylpiperazine is a chemical compound often used in scientific and industrial applications. Not much information is readily available about its specific properties or uses, as it is normally a component within a larger chemical mixture or process. It is identified by CAS registry number 56528-31-7. Although the nature, behavior, and safety of this chemical under various conditions are largely determined through scientific experimentation and observation, proper safe handling and usage instructions must always be strictly followed to minimize any potential risks or hazards. As with any chemical, it's important to have a thorough understanding of its properties and potential effects to ensure it is used in a safe and effective manner.

InChI:InChI=1/C13H28N2/c1-2-3-4-5-6-7-8-11-15-12-9-14-10-13-15/h14H,2-13H2,1H3

Upstream product

• 110-85-0 piperazine 
• 4282-42-2 1-iodononane 
• 111-66-0 oct-1-ene 
• 201230-82-2 carbon monoxide 
• 693-58-3 1-Bromononane 

Relevant articles and documents

Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents

The extensive use of fluconazole (FLC) and other azole drugs has caused the emergence and rise of azole-resistant fungi. The fungistatic nature of FLC in combination with toxicity concerns have resulted in an increased demand for new azole antifungal agents. Herein, we report the synthesis and antifungal activity of novel alkylated piperazines and alkylated piperazine-azole hybrids, their time-kill studies, their hemolytic activity against murine erythrocytes, as well as their cytotoxicity against mammalian cells. Many of these molecules exhibited broad-spectrum activity against all tested fungal strains, with excellent minimum inhibitory concentration (MIC) values against non-albicans Candida and Aspergillus strains. The most promising compounds were found to be less hemolytic than the FDA-approved antifungal agent voriconazole (VOR). Finally, we demonstrate that the synthetic alkylated piperazine-azole hybrids do not function by fungal membrane disruption, but instead by disruption of the ergosterol biosynthetic pathway via inhibition of the 14α-demethylase enzyme present in fungal cells.

ALKYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY

Described herein are D4 receptor-selective compounds of the general formula: STR1 wherein: A and B are independently selected, optionally substituted, unsaturated 5-or 6-membered, homo-or heterocyclic rings; X 1 is selected from CH 2, O, NH, S, C. dbd.O, CH--OH, CH--N(C 1-4 alkyl) 2, C=CHCl, C=CHCN, N--C 1-4 alkyl, N-acetyl, SO 2 and SO;X 2---is selected from N=, CH 2--, CH= and C(O);Y is selected from N and CH;R. sub.1 represents C 1-4 alkyl;n is 0, 1 or 2;q is 1 or 2; andZ is C 5-10 alkyl optionally substituted with OH, halo, C 1-4 alkyl or C 1-4 alkoxy and optionally incorporating a heteroatom selected from O, N and S;and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which D4 receptor stimulation is implicated, such as schizophrenia, is also described.

Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same

Novel trifluorothymidine derivatives having anti-cancer activities are disclosed. The trifluorothymidine derivatives of the present invention are represented by the formula [I]: (wherein R1 represents hydrogen atom or C1 - C4 alkyl group; R2 represents hydrogen atom, C1 - C30 saturated or unsaturated alkyl-substituted carbonyl group, alkyl-substituted benzoyl group, C1 - C4 alkyloxycarbonyl group; dimethylaminoethyloxycarbonyl group, C1 - C4 alkyloxymethyl group, butoxyethoxyacetyl group, benzyl group, C1 - C20 alkyl-substituted silyl group, silyl group substituted with C1 - C10 alkyl group and/or phenyl group, C1 - C30 cyclic or chain alkyl-substituted carbamoyl group, diethylaminopropylcarbamoyl group, N-alkylpiperazinylacetyl group, N-alkylprolyl group, valyl group, trityl group, alkyl-substituted phosphoryl group or propargyl group; R3 represents hydrogen atom, C1 - C4alkyl group, benzyl group, benzoyl group, C1 - C4 alkyloxy-substituted benzoyl group, furoyl group, C1 - C4 alkyloxymethyl group or C1 - C4 alkyl-substituted carbonyl group).